5:31 PM
 | 
May 08, 2009
 |  BC Extra  |  Top Story

Cervarix response higher than Gardasil

Data from a head-to-head Phase III trial in 1,106 healthy women ages 18-45 showed that Cervarix HPV vaccine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) produced a significantly higher immune response against HPV types 16 and 18 at 7 months compared to

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >